SOURCE: Invest in Denmark

June 21, 2005 11:55 ET

Danish Companies Show Latest Advancements at BIO 2005

Denmark's World Class Biocluster Key Location for Drug Discovery & Development

PHILADELPHIA, PA -- (MARKET WIRE) -- June 21, 2005 -- BIO 2005 Annual International Convention, Scandinavian Pavilion -- Booth 2149 -- Over 35 Danish biotech companies are exhibiting, partnering, and displaying their latest technology advancements and products at the BIO 2005 Annual International Convention in Philadelphia, PA, this week. Denmark is recognized as a world leader in drug discovery and development, as well as a leading center for research and clinical trials for diabetes, inflammation/immunology, neuroscience, and cancer.

"Denmark and a number of its promising biotech companies are making a strong presence at BIO 2005," stated Elisabeth Manford, Director of Invest in Denmark. "Our country has become one of the largest bioclusters in Europe for drug discovery and biologics by attracting the industry leading players to establish offices for R&D, pharmaceutical manufacturing, and clinical trials. U.S and international biocompanies choose Denmark because of its world-class infrastructure, educated workforce, flexible labor market, and a pro-business climate with a competitive cost structure."

Key areas of focus for Danish companies exhibiting at BIO 2005 include:

--  antibody analogues
--  bioinformatics
--  biologics
--  cancer drugs
--  CNS/Neuroscience Drugs
--  enzyme production
--  inflammation drugs
--  metabolic drugs
--  protein analysis
--  protein immobilization
--  vaccine development
Denmark Biotech Strengths - Reasons for International Companies to Locate There

- Low cost high quality on all parameters from science to government

--  Denmark has a large skilled and well-educated workforce with an output
    of 3000 graduate students within Life Science/year.
--  Strong R&D focus, collaborations with Pharmaceutical/biotech
    companies, and Universities.
--  Costs for clinical research are among the lowest in northern Europe.
--  Infrastructure - the Danish government has invested more than $10
    billion over the last 10 years to make the infrastructure around Copenhagen
    one of the most efficient in Europe.
--  World class engineering companies in pharmaceutical production
    facilities located in Denmark.
--  Drugs are Denmark's #1 export item and Denmark manufacture drugs
    according the FDA regulations for export to the U.S. market.
--  Strong history - first country in the world to develop biotech-
    specific legislation.
--  Flexible labor laws in contrast to most other European countries.
--  Denmark was elected the best country to conduct business in according
    to The Economist Intelligence Unit latest survey 2005.
Danish Companies/Organizations in Scandinavian Pavilion at BIO 2005
Ace Biosciences A/S      2159
Action Pharma A/S        2159
Alphalyse                2159
ALK-Abelló A/S           2149
bioTEAMsouth             2155
CMC Biopharmaceuticals   2149
HØIBERG A/S              2149
Invest in Iceland Agency 2049
Leo Pharma A/S           2049
Medicon Valley           2149
Medicon Valley Academy   2149
Medicon Valley Magazine  2149
MESH Technologies        2159
Niels Clauson-Kaas A/S   2149
NOVI A/S                 2159
Novo Nordisk A/S         2149
Novozymes Biopharma AB   2149
Nuevolution A/S          2149
Plougmann & Vingtoft     2149
Wiborg ApS               2149
Additional Danish Companies at Bio 2005
ACE BioSciences A/S
Bioneer A/S
ENKAM Pharmaceuticals A/S
Genmab AS
Neurosearch AS
Novo Ventures - Novo A/S
Novozymers A/S
NS Gene A/S
Nuevolution A/S
Nycomed Group
Pharmexa A/S
Santaris Pharma
Symphogen A/S
VersaMatrix A/S
Facts About Denmark

Copenhagen is the 5th largest airport in Europe and the most efficient, with travel from the airport to Copenhagen Grand Central Train Station taking just 12 minutes. A one-to-two hour flight will reach London, Paris, Helsinki, Oslo, Stockholm, Berlin, and the Baltic region. Copenhagen Airport was the best airport in the World in 2000 according to IATA.

A location in Denmark, which is part of Medicon Valley, provides all the benefits of being part of the 3rd largest Biotech cluster in Europe with access to capital, one of the most highly skilled and productive work forces in Europe, suppliers and customers in addition to tier 1 physical and communication infrastructure as well as effective Government.

Additionally, Denmark represents a very stable economy with flexible labor laws, competitive corporate tax laws, the most favorable tax regime for holding companies in Europe and a general low cost structure.

About Invest in Denmark

Invest in Denmark, headquartered in Copenhagen, is part of the Danish Trade Council in the Ministry of Foreign Affairs of Denmark. The organization focus is to maintain and attract foreign direct investment to Denmark, thereby strengthening the globalization of Danish business and increasing the level of competence and knowledge. We provide services to foreign companies considering the possibility of establishing business operations in Denmark, and provide potential investors with insight into the business opportunities that Denmark can offer. Invest in Denmark has offices throughout North America, Asia and Europe with U.S. offices located in New York and San Francisco. For more information, visit the Web site: or email: or call: 212-223-4545.

Contact Information

  • Company Contact:
    Invest in Denmark
    Gitte Pedersen
    Phone: 212-665-8626
    Cell: 917-873-2003
    Email: Email Contact

    Media Contact:
    TopSpin Communications, Inc.
    Joe Waldygo
    Phone: 480-632-5050
    Cell: 480-363-8774
    Email: Email Contact